Cognitive Trance, Hypnosis and Meditation in Oncology

NCT04873661 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2025-04-06

No results posted yet for this study

Summary

Patients with cancer often suffer from a symptom cluster, including pain, fatigue, sleep difficulties, emotional distress and cognitive impairments. In oncology settings, there is a growing interest in "mind-body" intervention, to relieve them in a non-pharmacological way. Hypnosis and meditation are two modified state of consciousness shown to positively this symptom cluster. Cognitive trance is also a modified state of consciousness, but is induced by body movements and/or vocalizations. Subjective reports of experts in cognitive trance showed a modification of self, emotion regulation, pain perception, attention and concentration. However, we still need to develop studies to better characterise this particular state of consciousness and its clinical applications. Our randomized-controlled trial aims at comparing both interventions in terms of (1) benefits on cancer patients' quality of life (pain, fatigue, sleep, distress, cognitive impairments), (2) phenomenological/subjective experiences and neurophysiological correlates, and (3) mechanisms involved in patients' responsiveness, based on the biopsychosocial model of hypnosis.

Conditions

Interventions

BEHAVIORAL

Hypnosis group intervention

See arm description

BEHAVIORAL

Cognitive trance group intervention

See arm description

BEHAVIORAL

Meditation group intervention

See arm description

Sponsors & Collaborators

  • FNRS (Télévie)

    collaborator UNKNOWN
  • Fondation contre le cancer

    collaborator UNKNOWN
  • Bial Foundation

    collaborator UNKNOWN
  • Centre Hospitalier Universitaire de Liege

    collaborator OTHER
  • University of Liege

    lead OTHER

Principal Investigators

  • Olivia Gosseries, PhD · ULiège

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04873661 on ClinicalTrials.gov